---
document_datetime: 2025-12-02 04:54:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-hydrochlorothiazide-zentiva.html
document_name: irbesartan-hydrochlorothiazide-zentiva.html
version: success
processing_time: 0.1643252
conversion_datetime: 2025-12-27 22:34:54.431688
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)

[RSS](/en/individual-human-medicine.xml/67076)

##### Authorised

This medicine is authorised for use in the European Union

irbesartan / hydrochlorothiazide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)](#news-on)
- [More information on Irbesartan Hydrochlorothiazide Zentiva](#more-information-on-irbesartan-hydrochlorothiazide-zentiva-865)
- [More information on Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Irbesartan Hydrochlorothiazide Zentiva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Irbesartan Hydrochlorothiazide Zentiva.

Expand section

Collapse section

## What is Irbesartan Hydrochlorothiazide Zentiva?

Irbesartan Hydrochlorothiazide Zentiva is a medicine that contains two active substances, irbesartan and hydrochlorothiazide. It is available as tablets (150 mg or 300 mg irbesartan and 12.5 mg hydrochlorothiazide; 300 mg irbesartan and 25 mg hydrochlorothiazide).

This medicine is the same as CoAprovel, which is already authorised in the European Union (EU). The company that makes CoAprovel has agreed that its scientific data can be used for Irbesartan Hydrochlorothiazide Zentiva.

## What is Irbesartan Hydrochlorothiazide Zentiva used for?

Irbesartan Hydrochlorothiazide Zentiva is used in adults who have essential hypertension (high blood pressure) that is not adequately controlled by irbesartan or hydrochlorothiazide alone. 'Essential' means that the hypertension has no obvious cause.

The medicine can only be obtained with a prescription.

## How is Irbesartan Hydrochlorothiazide Zentiva used?

The dose of Irbesartan Hydrochlorothiazide Zentiva to be used depends on the dose of irbesartan or hydrochlorothiazide that the patient was taking before. Doses higher than 300 mg irbesartan and 25 mg hydrochlorothiazide once a day are not recommended. Irbesartan Hydrochlorothiazide Zentiva may be added to some other treatments for hypertension.

## How does Irbesartan Hydrochlorothiazide Zentiva work?

Irbesartan Hydrochlorothiazide Zentiva contains two active substances, irbesartan and hydrochlorothiazide.

Irbesartan is an 'angiotensin-II-receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, irbesartan stops the hormone having an effect, allowing the blood vessels to widen.

Hydrochlorothiazide is a diuretic, which is another type of treatment for hypertension. It works by increasing urine output, reducing the amount of fluid in the blood and lowering the blood pressure.

The combination of the two active substances has an additive effect, reducing the blood pressure more than either medicine alone. By lowering the blood pressure, the risks associated with high blood pressure, such as having a stroke, are reduced.

## How has Irbesartan Hydrochlorothiazide Zentiva been studied?

Irbesartan on its own has been approved in the EU since 1997 under the names Karvea and Aprovel. It can be used with hydrochlorothiazide to treat hypertension. The studies of Karvea / Aprovel used with hydrochlorothiazide as separate tablets were used to support the use of Irbesartan Hydrochlorothiazide Zentiva. Further studies were also carried out with doses of 300 mg irbesartan in combination with 25 mg hydrochlorothiazide. The main measure of effectiveness was the reduction in diastolic blood pressure (the blood pressure measured between two heartbeats).

## What benefit has Irbesartan Hydrochlorothiazide Zentiva shown during the studies?

Irbesartan Hydrochlorothiazide Zentiva was more effective than placebo (a dummy treatment) and than hydrochlorothiazide alone in reducing diastolic blood pressure. Increasing the dose to 300 mg irbesartan and 25 mg hydrochlorothiazide may give a further decrease in blood pressure.

## What is the risk associated with Irbesartan Hydrochlorothiazide Zentiva?

The most common side effects with Irbesartan Hydrochlorothiazide Zentiva (seen in between 1 and 10 patients in 100) are dizziness, nausea (feeling sick) or vomiting, abnormal urination, fatigue (tiredness), and increases in blood urea nitrogen (BUN, a breakdown product of protein), creatinine (a breakdown product of muscle) and creatine kinase (an enzyme found in muscles). For the full list of all side effects reported with Irbesartan Hydrochlorothiazide Zentiva, see the package leaflet.

Irbesartan Hydrochlorothiazide Zentiva must not be used in people who are hypersensitive (allergic) to irbesartan, hydrochlorothiazide, sulfonamides, or any of the other ingredients. It must not be used in women who are more than three months pregnant. Its use during the first three months of pregnancy is not recommended. Irbesartan Hydrochlorothiazide Zentiva must also not be used in patients who have severe liver, kidney or bile problems, blood potassium levels that are too low or blood calcium levels that are too high.

Irbesartan Hydrochlorothiazide Zentiva in combination with aliskiren-containing medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment. Care must be taken when using Irbesartan Hydrochlorothiazide Zentiva with other medicines that have an effect on blood potassium levels. The full list of these medicines is given in the package leaflet.

## Why has Irbesartan Hydrochlorothiazide Zentiva been approved?

The CHMP decided that Irbesartan Hydrochlorothiazide Zentiva's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Irbesartan Hydrochlorothiazide Zentiva

The European Commission granted a marketing authorisation valid throughout the European Union for Irbesartan Hydrochlorothiazide Winthrop on 19 January 2007. The name of the medicine was changed to Irbesartan Hydrochlorothiazide Zentiva on 6 February 2012.

For more information about treatment with Irbesartan Hydrochlorothiazide Zentiva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Irbesartan Hydrochlorothiazide Zentiva : EPAR - Summary for the public

English (EN) (108.1 KB - PDF)

**First published:** 05/05/2009

**Last updated:** 20/09/2013

[View](/en/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-368)

български (BG) (140.98 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/bg/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_bg.pdf)

español (ES) (108.19 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/es/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_es.pdf)

čeština (CS) (136.29 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/cs/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_cs.pdf)

dansk (DA) (107.71 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/da/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_da.pdf)

Deutsch (DE) (109.33 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/de/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_de.pdf)

eesti keel (ET) (108.66 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/et/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_et.pdf)

ελληνικά (EL) (142.62 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/el/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_el.pdf)

français (FR) (111.44 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/fr/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_fr.pdf)

hrvatski (HR) (121.38 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/hr/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_hr.pdf)

italiano (IT) (107.56 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/it/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_it.pdf)

latviešu valoda (LV) (131.02 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/lv/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (134.58 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/lt/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_lt.pdf)

magyar (HU) (127.28 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/hu/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_hu.pdf)

Malti (MT) (136.49 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/mt/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_mt.pdf)

Nederlands (NL) (108.25 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/nl/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_nl.pdf)

polski (PL) (137.8 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/pl/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_pl.pdf)

português (PT) (108.33 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/pt/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_pt.pdf)

română (RO) (131.32 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/ro/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_ro.pdf)

slovenčina (SK) (135.78 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/sk/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_sk.pdf)

slovenščina (SL) (126.87 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/sl/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_sl.pdf)

Suomi (FI) (109 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/fi/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_fi.pdf)

svenska (SV) (109.68 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

20/09/2013

[View](/sv/documents/overview/irbesartan-hydrochlorothiazide-zentiva-epar-summary-public_sv.pdf)

## Product information

Irbesartan Hydrochlorothiazide Zentiva : EPAR - Product information

English (EN) (1.17 MB - PDF)

**First published:** 19/10/2009

**Last updated:** 18/06/2025

[View](/en/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-716)

български (BG) (1.5 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/bg/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_bg.pdf)

español (ES) (1.61 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/es/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_es.pdf)

čeština (CS) (1.18 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/cs/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_cs.pdf)

dansk (DA) (1017.16 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/da/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_da.pdf)

Deutsch (DE) (1.23 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/de/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_de.pdf)

eesti keel (ET) (970.03 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/et/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_et.pdf)

ελληνικά (EL) (1.92 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/el/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_el.pdf)

français (FR) (1.38 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/fr/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_fr.pdf)

hrvatski (HR) (1.34 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/hr/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_hr.pdf)

íslenska (IS) (1012.1 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/is/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_is.pdf)

italiano (IT) (1.56 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/it/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_it.pdf)

latviešu valoda (LV) (1.29 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/lv/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.68 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/lt/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_lt.pdf)

magyar (HU) (1.26 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/hu/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_hu.pdf)

Malti (MT) (2.02 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/mt/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_mt.pdf)

Nederlands (NL) (1.59 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/nl/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_nl.pdf)

norsk (NO) (989.17 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/no/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_no.pdf)

polski (PL) (1.35 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/pl/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_pl.pdf)

português (PT) (931.51 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/pt/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_pt.pdf)

română (RO) (1.18 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/ro/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_ro.pdf)

slovenčina (SK) (1.68 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/sk/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_sk.pdf)

slovenščina (SL) (1.23 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/sl/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_sl.pdf)

Suomi (FI) (1.04 MB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/fi/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_fi.pdf)

svenska (SV) (1012.49 KB - PDF)

**First published:**

19/10/2009

**Last updated:**

18/06/2025

[View](/sv/documents/product-information/irbesartan-hydrochlorothiazide-zentiva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000268656 17/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Irbesartan Hydrochlorothiazide Zentiva : EPAR - All Authorised presentations

English (EN) (31.92 KB - PDF)

**First published:** 05/02/2007

**Last updated:** 01/08/2012

[View](/en/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-955)

български (BG) (66.28 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/bg/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_bg.pdf)

español (ES) (31.39 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/es/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (44.32 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/cs/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (31.24 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/da/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (31.45 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/de/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (32.18 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/et/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (65.68 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/el/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_el.pdf)

français (FR) (31.46 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/fr/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (31.65 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/is/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (32.17 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/it/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (60.51 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/lv/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (60.04 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/lt/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (43.88 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/hu/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (58.13 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/mt/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (31.43 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/nl/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (30.96 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/no/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_no.pdf)

polski (PL) (45.31 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/pl/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_pl.pdf)

português (PT) (31.84 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/pt/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_pt.pdf)

română (RO) (61.15 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/ro/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (61.09 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/sk/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (31.71 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/sl/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (31.56 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/fi/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (31.79 KB - PDF)

**First published:**

05/02/2007

**Last updated:**

01/08/2012

[View](/sv/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-zentiva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop) Active substance

- irbesartan
- hydrochlorothiazide

International non-proprietary name (INN) or common name

- irbesartan
- hydrochlorothiazide

Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09DA04

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.

## Authorisation details

EMA product number EMEA/H/C/000783 Marketing authorisation holder

sanofi-aventis groupe

sanofi-aventis groupe

Marketing authorisation issued 18/01/2007 Revision 36

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Irbesartan Hydrochlorothiazide Zentiva: EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (151.37 KB - PDF)

**First published:** 29/01/2025

**Last updated:** 18/06/2025

[View](/en/documents/procedural-steps-after/irbesartan-hydrochlorothiazide-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Irbesartan Hydrochlorothiazide Zentiva: EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (377.09 KB - PDF)

**First published:** 26/10/2009

**Last updated:** 29/01/2025

[View](/en/documents/procedural-steps-after/irbesartan-hydrochlorothiazide-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Angiotensin-II-receptor antagonists (sartans) : Scientific conclusions - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

English (EN) (119.28 KB - PDF)

**First published:** 05/07/2021

[View](/en/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

[Other languages (22)](#file-language-dropdown-472)

български (BG) (145.18 KB - PDF)

**First published:**

05/07/2021

[View](/bg/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_bg.pdf)

español (ES) (125.85 KB - PDF)

**First published:**

05/07/2021

[View](/es/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_es.pdf)

čeština (CS) (139.02 KB - PDF)

**First published:**

05/07/2021

[View](/cs/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_cs.pdf)

dansk (DA) (126.81 KB - PDF)

**First published:**

05/07/2021

[View](/da/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_da.pdf)

Deutsch (DE) (131.05 KB - PDF)

**First published:**

05/07/2021

[View](/de/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_de.pdf)

eesti keel (ET) (123.85 KB - PDF)

**First published:**

05/07/2021

[View](/et/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_et.pdf)

ελληνικά (EL) (139.5 KB - PDF)

**First published:**

05/07/2021

[View](/el/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_el.pdf)

français (FR) (127.12 KB - PDF)

**First published:**

05/07/2021

[View](/fr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fr.pdf)

hrvatski (HR) (142.87 KB - PDF)

**First published:**

05/07/2021

[View](/hr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hr.pdf)

italiano (IT) (126.56 KB - PDF)

**First published:**

05/07/2021

[View](/it/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_it.pdf)

latviešu valoda (LV) (147.7 KB - PDF)

**First published:**

05/07/2021

[View](/lv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lv.pdf)

lietuvių kalba (LT) (148.34 KB - PDF)

**First published:**

05/07/2021

[View](/lt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lt.pdf)

magyar (HU) (137.17 KB - PDF)

**First published:**

05/07/2021

[View](/hu/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hu.pdf)

Malti (MT) (151.21 KB - PDF)

**First published:**

05/07/2021

[View](/mt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_mt.pdf)

Nederlands (NL) (127.53 KB - PDF)

**First published:**

05/07/2021

[View](/nl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_nl.pdf)

polski (PL) (137.7 KB - PDF)

**First published:**

05/07/2021

[View](/pl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pl.pdf)

português (PT) (128.87 KB - PDF)

**First published:**

05/07/2021

[View](/pt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pt.pdf)

română (RO) (143.59 KB - PDF)

**First published:**

05/07/2021

[View](/ro/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_ro.pdf)

slovenčina (SK) (135.07 KB - PDF)

**First published:**

05/07/2021

[View](/sk/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sk.pdf)

slovenščina (SL) (149.74 KB - PDF)

**First published:**

05/07/2021

[View](/sl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sl.pdf)

Suomi (FI) (125.84 KB - PDF)

**First published:**

05/07/2021

[View](/fi/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fi.pdf)

svenska (SV) (126.99 KB - PDF)

**First published:**

05/07/2021

[View](/sv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

Reference Number: EMA/47245/2021

English (EN) (362.31 KB - PDF)

**First published:** 02/03/2021

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

Irbesartan Hydrochlorothiazide Zentiva : EPAR - Scientific conclusions

English (EN) (99.42 KB - PDF)

**First published:** 23/05/2019

[View](/en/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_en.pdf)

[Other languages (22)](#file-language-dropdown-216)

български (BG) (136.15 KB - PDF)

**First published:**

23/05/2019

[View](/bg/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_bg.pdf)

español (ES) (98.31 KB - PDF)

**First published:**

23/05/2019

[View](/es/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_es.pdf)

čeština (CS) (131.08 KB - PDF)

**First published:**

23/05/2019

[View](/cs/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_cs.pdf)

dansk (DA) (96.12 KB - PDF)

**First published:**

23/05/2019

[View](/da/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_da.pdf)

Deutsch (DE) (100.2 KB - PDF)

**First published:**

23/05/2019

[View](/de/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_de.pdf)

eesti keel (ET) (94.4 KB - PDF)

**First published:**

23/05/2019

[View](/et/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_et.pdf)

ελληνικά (EL) (142.79 KB - PDF)

**First published:**

23/05/2019

[View](/el/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_el.pdf)

français (FR) (97.56 KB - PDF)

**First published:**

23/05/2019

[View](/fr/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_fr.pdf)

hrvatski (HR) (125.02 KB - PDF)

**First published:**

23/05/2019

[View](/hr/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_hr.pdf)

italiano (IT) (95.54 KB - PDF)

**First published:**

23/05/2019

[View](/it/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_it.pdf)

latviešu valoda (LV) (130.68 KB - PDF)

**First published:**

23/05/2019

[View](/lv/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_lv.pdf)

lietuvių kalba (LT) (130.84 KB - PDF)

**First published:**

23/05/2019

[View](/lt/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_lt.pdf)

magyar (HU) (119.82 KB - PDF)

**First published:**

23/05/2019

[View](/hu/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_hu.pdf)

Malti (MT) (133.78 KB - PDF)

**First published:**

23/05/2019

[View](/mt/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_mt.pdf)

Nederlands (NL) (99.3 KB - PDF)

**First published:**

23/05/2019

[View](/nl/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_nl.pdf)

polski (PL) (130.65 KB - PDF)

**First published:**

23/05/2019

[View](/pl/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_pl.pdf)

português (PT) (96.47 KB - PDF)

**First published:**

23/05/2019

[View](/pt/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_pt.pdf)

română (RO) (128.25 KB - PDF)

**First published:**

23/05/2019

[View](/ro/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_ro.pdf)

slovenčina (SK) (119.14 KB - PDF)

**First published:**

23/05/2019

[View](/sk/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_sk.pdf)

slovenščina (SL) (124.14 KB - PDF)

**First published:**

23/05/2019

[View](/sl/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_sl.pdf)

Suomi (FI) (97.12 KB - PDF)

**First published:**

23/05/2019

[View](/fi/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_fi.pdf)

svenska (SV) (96.85 KB - PDF)

**First published:**

23/05/2019

[View](/sv/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-epar-scientific-conclusions_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report

Adopted

Reference Number: EMA/217823/2019

English (EN) (531.32 KB - PDF)

**First published:** 02/05/2019

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf)

Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)-H-C-PSUSA-00001653-201609 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisat...

Reference Number: EMA/715525/2017

English (EN) (75.5 KB - PDF)

**First published:** 07/11/2017

**Last updated:** 07/11/2017

[View](/en/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-psusa-00001653-201609-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisat_en.pdf)

Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)-H-C-783-A31-75: EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed e...

English (EN) (48.81 KB - PDF)

**First published:** 30/09/2014

**Last updated:** 30/09/2014

[View](/en/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_en.pdf)

[Other languages (22)](#file-language-dropdown-964)

български (BG) (87.49 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/bg/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/es/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/cs/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/da/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/de/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/et/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/el/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/fr/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/hr/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/it/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/lv/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/lt/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/hu/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/mt/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/nl/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/pl/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/pt/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/ro/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/sk/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/sl/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/fi/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/sv/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-783-a31-75-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-e_sv.pdf)

Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)-H-C-A31-75 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/PRAC/294920/2014

English (EN) (301.42 KB - PDF)

**First published:** 30/09/2014

**Last updated:** 30/09/2014

[View](/en/documents/variation-report/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop-h-c-a31-75-epar-assessment-report-article-31_en.pdf)

Irbesartan Hydrochlorothiazide Zentiva-H-C-783-II-69 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/377924/2013

English (EN) (123.98 KB - PDF)

**First published:** 20/09/2013

**Last updated:** 20/09/2013

[View](/en/documents/variation-report/irbesartan-hydrochlorothiazide-zentiva-h-c-783-ii-69-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Irbesartan Hydrochlorothiazide Zentiva

Adopted

Reference Number: EMA/CHMP/388295/2013

English (EN) (66.48 KB - PDF)

**First published:** 28/06/2013

**Last updated:** 28/06/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-irbesartan-hydrochlorothiazide-zentiva_en.pdf)

## Initial marketing authorisation documents

Irbesartan Hydrochlorothiazide Winthrop : EPAR - Procedural steps taken before authorisation

English (EN) (21.07 KB - PDF)

**First published:** 05/02/2007

[View](/en/documents/procedural-steps/irbesartan-hydrochlorothiazide-winthrop-epar-procedural-steps-taken-authorisation_en.pdf)

Irbesartan Hydrochlorothiazide Winthrop : EPAR - Scientific Discussion

English (EN) (23.76 KB - PDF)

**First published:** 05/02/2007

**Last updated:** 05/02/2007

[View](/en/documents/scientific-discussion/irbesartan-hydrochlorothiazide-winthrop-epar-scientific-discussion_en.pdf)

#### News on Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2013) 28/06/2013

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive](/en/news/european-medicines-agency-concludes-benefit-risk-balance-angiotensin-ii-receptor-antagonists-remains-positive) 20/10/2011

#### More information on Irbesartan Hydrochlorothiazide Zentiva

- [Renin-angiotensin-system (RAS)-acting agents: Article-31 referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer

Reference Number: EMA/CHMP/834168/2011

English (EN) (511.41 KB - PDF)

**First published:** 20/10/2011

**Last updated:** 11/05/2017

[View](/en/documents/opinion-any-scientific-matter/questions-answers-review-angiotensin-ii-receptor-antagonists-risk-cancer_en.pdf)

#### More information on Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)
- [Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group - referral](/en/medicines/human/referrals/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 29/01/2025

## Share this page

[Back to top](#main-content)